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Background: The optimal surgical treatment for osteonecrosis of the femoral head has yet to be
elucidated. To evaluate the role of femoral ﬁxation techniques in hip resurfacing, we present a com-
parison of the results for 2 consecutive groups: group 1 (75 hips) received hybrid hip resurfacing
implants with a cemented femoral component; group 2 (103 hips) received uncemented femoral
components. Both groups received uncemented acetabular components.
Methods: We retrospectively analyzed our clinical database to compare failures, reoperations, compli-
cations, clinical results, metal ion test results, and X-ray measurements. Using consecutive groups caused
time interval bias, so we required all group 2 patients to be at least 2 years out from surgery; we
compared results from 2 years and ﬁnal follow-up.
Results: Patient groups matched similarly in age, body mass index, and percent female. Despite similar
demographics, the uncemented, group 2 cases showed a lower raw failure rate (0% vs 16%; P < .0001), a
lower 2-year failure rate (0% vs 7%; P ¼ .04), and a superior 8-year implant survivorship (100% vs 91%;
log-rank P ¼ .0028; Wilcoxon P ¼ .0026). In cases that did not fail, patient clinical (P ¼ .05), activity
(P ¼ .02), and pain scores (P ¼ .03), as well as acetabular component position (P < .0001), all improved in
group 2, suggesting advancements in surgical management. There were no cases of adverse wear-related
failure in either group.
Conclusion: This study demonstrates a superior outcome for cases of osteonecrosis with uncemented hip
resurfacings compared to cases employing hybrid devices.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Following success in elderly, inactive patients in the 1950s, Sir
John Charnley's stemmed total hip arthroplasty (THA) design
received acclaim and wide consideration as the paradigm of hip
replacement prostheses; yet, he cautioned against use of THA in
younger, active patients [1]. As Charnley predicted, standard stem-
med THA exhibits inferior durability in these patients [2]. Hip
resurfacing arthroplasty (HRA) offers an alternative to THA in young
patients, providing a more functional [3], bone-preserving method.
HRA offers numerous theoretical advantages, including minimal
bone resection [4], greater stability [5,6], less thigh pain [7,8],ed for this manuscript.
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r Inc. This is an open access articleavoidance of stress shielding [9,10], ease of revision [11], resumption
of high range-of-motion activities [12,13], and more nearly-normal
gait [14-16]. During its nascent stages, HRA provided discouraging
results [17], and as a result, many surgeons abandoned the concept
entirely. During unsuccessful, early HRA procedures, the poor
performance of polytetraﬂuoroethylene and metal-on-polyethylene
bearings revealed the need for a reliable bearing material if a suc-
cessful HRA procedure was to be realized [18,19]. In 1991, McMinn
played an instrumental role in reviving HRA with a new cobalt-
chromium (Co-Cr) metal-on-metal (MOM) implant system [20].
Despite excellent results for hybrid Co-Cr resurfacing implants
using femoral cement in young men with osteoarthritis (OA) [21],
outcomes for patients with osteonecrosis (ON) proved less favor-
able [22,23]. Our previous study revealed that the most common
failure mode in patients with ON was femoral cement loosening
[24]. Subsequently, our study on HRA patients of all diagnoses
found that loosening occurred in 3% of cemented femoral compo-
nents by 10 years postoperatively [5]. To address femoral cement
ﬁxation as a potential weak link in the MOM hip-resurfacing
construct, we collaborated with Biomet to develop theunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic Information.
Variable Group 1 Group 2 P Value
Number of cases 75 103 d
Date range January 2001-August 2013 d
Demographics
Age 46 ± 12 45 ± 10 .588
Body mass index 27 ± 4 28 ± 5 .141
Female cases (# hips, %) 19/75 (25) 19/103 (18) .267
Harris hip score (preoperative) 49 ± 12 53 ± 14 .042*
Diagnosis
AVN (I) 0/75 (0%) 1/103 (1%) .390
AVN (II) 2/75 (3%) 6/103 (6%) .317
AVN (III) 32/75 (43%) 35/103 (34%) .238
AVN (IV) 30/75 (40%) 61/103 (59%) .011*
Unrecorded Ficat grade 11/75 (15%) 0/103 (0%) <.0001*
Asterisk (*) represents a statistical difference.
Avascular necrosis (AVN) grades are shown.
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uncemented, fully porous-coated femoral component for MOM
HRA. Its intended design pairs it together with the uncemented
MagnumTM acetabular component. We ﬁrst employed this porous
ingrowth device in March 2007 and have continued to use it
exclusively in all total resurfacing patients since 2008 [4].
The relative merits of these and other implants employing
porous ingrowth ﬁxation vs those ﬁxed with poly-
methylmethacrylate cement continue to be debated by surgeons
and scientists worldwide. Porous ﬁxation was ﬁrst introduced in
the 1970s, and now, approximately 60% to 90% of the 300,000 THAs
performed per year in the United States involve these uncemented
components [25]. As THAs move toward eliminating cement
entirely, many HRA systems still continue to use femoral cement
[24,26]. Although the results of cemented HRA implants are satis-
factory for cases of OA [16,27], femoral failure in HRA remains a
problem in high-risk, ON patients. The exothermic reaction
generated from cement curing may lead to damage of the femoral
head [28] and could inﬂuence these failure modes. A benchtop
study [29] determined that increased temperature develops inTable 2
Metal Ion Results and Associated Reference Values.
Variables Group 1 (Hybrid)
Unilateral (N ¼ 18) Bilateral (N ¼ 17)
Co (mg/L)* 1.2 ± 0.62 4.6 ± 10.6
Cr (mg/L)* 0.9 ± 0.60 3.5 ± 3.33
Test date (y postoperative)* 7.9 ± 2.07 8.6 ± 1.36
#, % Patients tested 35 (47%)
#, % Levels converted 4 (22%) 3 (17%)
Total normal (#, %) 15 (43%)
Normal (#, %) 12 (67%) 3 (17%)
Optimal (#, %) 18 (100%) 16 (89%)
Acceptable (#, %) 0 (0%) 1 (5.5%)
Problematic (#, %) 0 (0%) 0 (0%)
Potentially toxic (#, %) 0 (0%) 0 (0%)
Normala Optimalb
Unilateral
Co (mg/L) <1.5 <4.0
Cr (mg/L) <1.5 <4.6
Bilateral
Co (mg/L) <1.5 <5.0
Cr (mg/L) <1.5 <7.4
Statistically signiﬁcant P values are bolded and denoted by an asterisk (*).
a Laboratory normal for patients without metal bearings.
b According to DeSmet/van der Straeten.
c According to our previous analysis.cystic defects ﬁlled with cement, conﬁrming the suspected
hypothesis that cement results in thermal damage of the femoral
head. In another study, the same author reported a higher inci-
dence of femoral failures when cysts are present [28]. In our own
study of femoral complications with head cysts, we found no dif-
ference in failure rate when cysts were present or not, but our
technique involved ﬁlling cysts with acetabular bone graft before
cementing [30]. This discrepancy between publications also sup-
ports the hypothesis that thermal injury from cement may be a
causative factor in femoral failures after resurfacing. Hybrid ﬁxation
for MOM hip resurfacing is the current standard, but they exhibit a
higher failure rate when implanted into patients with ON. Critics of
uncemented femoral resurfacings contend that osteonecrotic
femoral heads lack adequate blood supply to allow bone ingrowth
and stable ﬁxation into a porous coating. In our experience, how-
ever, we encounter live, bleeding bone at the base of the femoral
head in all resurfacing cases for ON. If the femoral head were truly
dead, we suggest that all implants would migrate radiographically
and be symptomatic by 2-year follow-up.
The primary goal of this study is to examine 3 hypotheses on the
reduction of femoral failure in resurfacing of the necrotic hip: First,
uncemented ﬁxation with a fully porous-coated implant will
eliminate cement-related failures caused by thermal bone necrosis,
cement toxicity to bone, or cement fatigue failure. Next, porous
femoral implants will achieve stable implant ﬁxation as evidenced
by lack of migration or stem radiolucency at 2 years postoperation.
Lastly, using a completely uncemented resurfacing system will
eliminate both early and late femoral failure modes.Materials and Methods
Patients and Methods
From January 2001 to August 2013, a single surgeon performed
3262 HRA procedures. Of these, we identiﬁed 178 cases (5.5%) in
150 patients with a primary diagnosis of ON as our study group
from the prospective database. Choosing August 2013 as a cutoff
allowed at least 2 years of follow-up for each patient. We offeredGroup 2 (Uncemented) P Values Between Groups
1 and 2
Unilateral (N ¼ 37) Bilateral (N ¼ 24) Unilateral Bilateral
3.1 ± 12.9 1.4 ± 0.69 .5369 .1463
1.3 ± 3.50 1.5 ± 0.91 .6337 .0077*
3.0 ± 1.47 2.7 ± 0.91 <.0001* <.0001*
61 (59%) .0969
6 (16%) 5 (21%) .5892 .8026
39 (64%) .0455*
31 (84%) 8 (33%) .1499 .2627
35 (95%) 24 (100%) .3173 .2301
1 (2.7%) 0 (0%) .4839 .2301
0 (0%) 0 (0%) 1.000 1.000
0 (0%) 0 (0%) 1.000 1.000
Acceptablec Problematicc Potentially Toxicb
4-10 10-20 >20
4.6-10 10-20 >20
5-10 10-20 >20
7.4-10 10-20 >20
Fig. 1. Pelvic X-ray of a male patient with a cemented Corin device in their right hip
from 2003 and an uncemented Biomet ReCapTM device in their left hip from 2009. AIA,
acetabular inclination angle.
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long as two-thirds of the femoral head was estimated to be viable.
After the initial success of the uncemented component [24,31], we
expanded the indication to include patients with only half of the
head viable. All resurfacings employed an uncemented acetabular
component. Between January 2001 and January 2008, 75 HRA
procedures were performed in 64 patients using a cemented
femoral component (group 1). The uncemented femoral ReCapTM
component became available in March 2007 and was used in
subsequent cases; this fully porous device was used exclusively
beginning in January 2008. Between March 2007 and August 2013,
103 fully uncemented HRA procedures were performed in 86
patients (group 2). Magnum components, which are approved as a
dual-mobility device, were used in an off-label fashion.
Demographic information and grade of ON according to Ficat's
classiﬁcation [32] are listed in Table 1. Institutional review boardFig. 2. Kaplan-Meier survivorship analysis using revision as an endpoint. Survivorship at 8 y
log-rank test (P value ¼ .0028) and Wilcoxon test (P value ¼ .0026) revealed femoral ﬁxat
postulate that cemented ﬁxation of the femoral component is the most signiﬁcant risk facto
deaths unrelated to the patients' hip arthroplasties. An asterisk (*) represents a statistical dapproval was obtained from Sisters of Charity Providence Hospitals,
Columbia, South Carolina.Implants
Two HRA devices were used in group 1; these include the hybrid
Corin Cormet 2000 (Corin Group, Cirencester, Gloucestershire,
United Kingdom) in the ﬁrst 43 cases and the cemented ReCapTM
with the uncemented MagnumTM (Biomet, Warsaw, IN) in the next
32 cases. Starting in March 2007, the fully porous-coated
ReCapTM-MagnumTM was used in all 103 uncemented cases.
The metallurgical composition of the Biomet system is high-
carbon (0.2%) cast Co-Cr alloy without heat treatment. Each indi-
vidual component was quality tested, with surface roughness less
than 0.5 mm and a radial clearance of 75 mm. The ReCapTM femoral
component has a hemisphere undersurface on top of a cylindrical
section. The cylindrical stem is 8 mm in diameter. The apex of each
component is 6-mm thick, tapering to 0 at the head-neck junction.
The cemented femoral component has a grit blast Co-Cr under-
surface with a machined radial gap of 0.5 mm for cement. The
uncemented femoral component has a titanium plasma-spray plus
hydroxyapatite coating for enhanced bone ingrowth. Similar
femoral tools are used, but the uncemented femoral component has
a 0.5-mm radial press ﬁt over the machined bone surface. The
femoral instrumentation was the ﬁrst designed using a measured
resection philosophy. This allows the surgeon to reproduce femoral
length or to increase or decrease it by up to 6mm to correct formild
deformity.
This was also the ﬁrst system to offer 2-mm increment sizing to
allow more accurate matching of the implants to the patient's
particular anatomy, with femoral component sizes ranging from 38
to 60 mm. A matching MagnumTM acetabular component was
originally available for each femoral size, and beginning in 2007, anears was 88% for the hybrid group and 100% for the uncemented group. Results of the
ion method (cemented/uncemented) is a signiﬁcant factor affecting survivorship. We
r in HRA. “H” stands for hybrid and “U” stands for uncemented. White circles represent
ifference. HRA, hip resurfacing arthroplasty.
Fig. 3. Kaplan-Meier survivorship analysis grouped by implant type using revision as an endpoint. Results of the log-rank test (P value < .0001) and Wilcoxon test (P value < .0001)
revealed difference in survivorship is signiﬁcant between the least (uncemented ReCapTM) and most (cemented Corin) frequently failed groups. White circles represent deaths
unrelated to the patients' hip arthroplasties. An asterisk (*) represents a statistical difference.
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for each size.
The acetabular component is 3-mm thick at the equator and 6-
mm thick at the pole, including the porous coating. Additional
thickness at the apex increases stiffness of the components,
decreasing deformation during impaction. The porous coating is
titanium-plasma spray to allow for bone ingrowth. Four pairs of
small ﬁns are present to add rotational control. The acetabular
bearing proﬁle arc ranges from 154.6 in the smallest component to
163.6 in the largest component. These implants are slightly
thinner than most others on the market.
The Corin device is no longer sold. It had similar metallurgy as
the Biomet devices but was heat treated. The femoral implant was
cemented employing a grit blast femoral component and
instruments to cut a line-to-line ﬁt. Three derotational longitudinal
splines were present. The acetabular component had a 2-mm rim
ﬂare and 3 peripheral thick ﬁns, and the coating was dual titanium-
plasma spray with hydroxyapatite. Coverage arcs were similar to
the Biomet device.
Procedure
All HRA cases were performed through the posterior approach
as previously described [33]. Loose necrotic bone and cystic soft
tissue were removed, and well-ﬁxed necrotic bone was bored into
with a 1/8-inch drill. Cement technique in group 1 included
applying high-viscosity cement in thin layers to both implant and
bone immediately after mixing, and the segmental bone defect was
ﬁlled with cement. A cement trough was present on the inferior
surface of the head for cement to escape. In group 2, defects wereﬁlled with acetabular reamings before impacting the uncemented
femoral component.
Postoperative Protocol
Weight bearing was advanced as tolerated by the patient. For
most patients, crutches were used for 2 weeks and a cane for 2
weeks thereafter. There was no formal physical therapy required
following hospital discharge. Unlimited activity was allowed at 6
months after surgery. The use of multimodal painmanagement and
comprehensive blood management protocols eliminated the need
for transfusion and accelerated recovery. Since 2012, resurfacing
has been performed as an outpatient procedure on select patients.
Metal Ion Testing
We use our database to collect blood, serum, and plasmametal
ion test results, which we routinely ask of our patients at 2 years
postoperation. We initiated routine ion testing in 2007, and we
also recommended ion testing at least once for all patients
operated on before this time. As previous reports suggest, we use
metal ion levels as indicators for potential failure due to excessive
implant wear, a phenomenon we refer to as adverse wear-related
failure (AWRF) [34]. We used whole blood ion levels for all
comparisons, and in cases with only serum or plasma levels
recorded, results were converted to whole blood ion levels by
Smolders' method [35]. In our opinion, the most scientiﬁcally
valid blood ion data and guidelines have been published by
DeSmet and Van der Straeten [36]; therefore, we employed their
methods to categorize ion levels as either “optimal” or
Fig. 4. Kaplan-Meier survivorship analysis for Biomet implants only using revision as an endpoint. Results of the log-rank test (P value ¼ .009) and Wilcoxon test (P value ¼ .01)
show that the uncemented ReCapTM device has signiﬁcantly greater survivorship than its uncemented counterpart. White circles represent deaths unrelated to the patients' hip
arthroplasties. An asterisk (*) represents a statistical difference.
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our own previous research and deﬁned whole blood ion levels
<10 mg/L as “acceptable” and those 10 mg/L as “problematic”
[37-39]. In all, we established 5 different ion level categories:
normal, optimal, acceptable, problematic, and potentially toxic
(See Table 2 legend for metal ion reference values).Clinical and Radiologic Analysis
Ofﬁce or remote follow-up was requested of all patients at 6
weeks, 1 and 2 years, and every other year thereafter. A clinical
questionnaire, radiograph analysis, and a physical examination
testing range-of-motion and strength were performed at each visit;
physical examinations were no longer completed routinely on
remote follow-ups after 1 year. We used the OrthoTrack database
(Midlands Orthopaedics, Columbia, SC) for collection and analysis
of the demographic, clinical, metal ion, and radiographic data.
Patient questionnaires collected information to calculate the
following scores for clinical evaluation: Harris hip score for
functional assessment (HHS) [40], University of California, Los
Angeles (UCLA) activity score [41], and visual analog scale (VAS)
pain score for normal and worst days [42]. UCLA activity scores
measure activity level after surgery on a scale from 1 to 10, for
which 10 represent the highest level of activity; VAS pain scores
rate the level of pain from 0 to 10, with 0 representing no pain and
10 representing maximum, debilitating pain.
Supine and standing anterior-posterior pelvis and lateral ra-
diographs are taken and analyzed for component position, shifting,
and radiolucencies. The acetabular inclination angle (AIA) isdetermined by taking the angle between a measurement line
running across the face of the acetabular component and a refer-
ence line horizontal across the inferior pubic rami (Fig. 1). All
measurements were taken using OrthoTrack (Midlands
Orthopaedics) and InteleViewer (InteleRAD, Chicago, IL).
Statistical Analysis
Statistical analyses were performed using Microsoft® Excel
(Microsoft, Redmond, WA) and JMP® (SAS, Cary, NC). Paired,
2-tailed Student t-tests were performed to ﬁnd signiﬁcant differ-
ences between numeric variables, and chi-square analyses were
used to determine differences in categorical variables. Two-sample
proportion Z-tests were used to compare ratios between the 2
groups. All tests were carried out at a ¼ 0.05. Kaplan-Meier (KM)
survivorship curves were generated using revision as an endpoint
to estimate postoperative survival rates of implants. A log-rank test
and a Wilcoxon test, at a ¼ 0.05, were performed to test whether
the implant survivorships were statistically different.
Results
KM implant survivorship (Fig. 2) at 8 years using revision as an
endpoint was 100% for group 2, compared to 91% for group 1
(log-rank P ¼ .0028; Wilcoxon P ¼ .0026). Two-year KM implant
survivorship using revision as an endpoint was 100% for
uncemented group 2 and 93% for hybrid group 1 (P ¼ .04). We
present KM survivorship grouped by implant type for all failures
(Fig. 3), for Biomet implants only (Fig. 4), for cemented femoral
Fig. 5. Kaplan-Meier survivorship analysis for cemented implants only using femoral revision as an endpoint. Results of the log-rank test (P value ¼ .75) and Wilcoxon test (P
value ¼ .75) show that there is no signiﬁcant difference in overall femoral failures between cemented devices. This supports that the reduction of femoral failures over time is not a
result of improved surgeon experience but rather the elimination of cemented ﬁxation. White circles represent deaths unrelated to the patients' hip arthroplasties. An asterisk (*)
represents a statistical difference.
Fig. 6. Kaplan-Meier survivorship analysis for uncemented vs grouped cemented implants using only femoral revision as an endpoint. Results of the log-rank test (P value ¼ .05)
andWilcoxon test (P value ¼ .05) show that uncemented ﬁxation has signiﬁcantly fewer femoral failures. White circles represent deaths unrelated to the patients' hip arthroplasties.
An asterisk (*) represents a statistical difference.
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Table 3
Summary of All Failures.
Mode of Failure Group 1 Group 2 P Value
Total failures 12/75; 16% 0/103; 0% <.0001*
Femoral failure
Femoral component loosening 5/75; 7% 0/103; 0% .008*
Acetabular failure
Acetabular component loosening 2/75; 3% 0/103; 0% .095
Other failure
Unexplained pain 1/75; 1% 0/103; 0% .238
Deep infection (hematogenous, late) 2/75; 3% 0/103; 0% .095
Psoas tendonitis 1/75; 1% 0/103; 0% .238
Recurrent dislocation 1/75; 1% 0/103; 0% .238
Cases that resulted in revision of the HRA replacement were considered failures.
An asterisk (*) represents a statistical difference.
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Four ON patients, all from group 1, died of causes unrelated to their
hip arthroplasties.
Failures requiring component revision are listed in Table 3. No
cases in group 2 failed, whereas in group 1, 16% of hips (12/75)
failed (P < .0001). The most commonmode of failure was loosening
of the femoral component (5/75; 6.7%), accounting for 42% of all
failures. All 5 femoral failures were revised to THA. Two of the
group 1 failures (2/75; 2.7%) were caused by loosening of the
acetabular component: 1 failure occurred at 5 years and was
revised to a THA; the other occurred at 8 years andwas treatedwith
an acetabular component revision. Five cases failed due to other
causes and were all converted to THA. These included 2 cases of
late, hematogenous infections (2/75; 2.7%), a recurrent dislocation
revised by another surgeon (1/75; 1.3%), 1 case of unexplained pain
(1/75; 1.3%), and 1 case of psoas tendonitis (1/75; 1.3%). The 39-
year-old female with unexplained pain presented slightly
elevated ion levels of Co ¼ 11.9 mg/L and Cr ¼ 7.6 mg/L; at revision
surgery, components were found well ﬁxed, and there were no
signs of metallosis. Ion levels were resolved to optimal levels by 3
months postoperation. The 52-year-old patient with psoas
tendonitis was revised 8 years after her original surgery, reported
metal ion levels of Co ¼ 2.1 mg/L and Cr ¼ 2.0 mg/L, and her implant
components were found to be well ﬁxed during revision surgery.
Reoperations and other complications not requiring surgery are
reported in Table 4. Group 1 hip-related complications occurred in
2.7% of cases (2/75); there was no signiﬁcant difference in this
frequency of complications compared with group 2. One hybrid-
group patient suffered a late, nondisplaced, greater trochanteric
fracture that healed with conservative treatment, and the otherTable 4
Summary of Complications and Reoperations.
Reason for Complication/Reoperation Group 1 Group 2 P Value
Total 2/75; 3% 4/103; 4% .659
Complications
Shift in acetabular component
position (asymptomatic)
0/75; 3% 2/103; 2% .226
IT fracture (late) 1/75; 1% 0/103; 0% .238
Nerve palsy 0/75; 0% 0/103; 0% 1.000
DVT/PE 0/75; 0% 0/103; 0% 1.000
Reoperations
Femoral fracture (late) 1/75; 1% 0/103; 0% .238
Superﬁcial infection (early) 0/75; 0% 1/103; 1% .389
Deep infection (early) 0/75; 0% 0/103; 0% 1.000
Wound necrosis 0/75; 0% 1/103; 1% .389
Complications were separated into 2 categories: complications that were observed
and those requiring reoperation.
An asterisk (*) represents a statistical difference.
DVT, deep venous thrombosis; PE, pulmonary embolism; IT, intertrochanteric.patient suffered a femoral shaft fracture 14 years after resurfacing
and was treated with open plating.
Group 2 hip-related complications occurred in 4% of cases (4/
103). One patient developed a superﬁcial infection and was cured
surgically without implant removal. Another patient incurred
wound necrosis, which was treated with plastic surgery without
loss of the implant. In 2 cases, signiﬁcant shifting of the acetabular
component occurred within several days postoperatively but
quickly stabilized, and both patients were asymptomatic with
optimal metal ion levels.
Clinical and radiographic data from most recent follow-up
visits are summarized in Table 5. Average postoperative HHS
scores for both groups signiﬁcantly improved from before sur-
gery (P < .0001), and most of the patients (4/8 group 1, 30/60
group 2 follow-up patients; 50% for both groups) resumed active
lifestyles (UCLA  7) by 2 years postsurgery. Average post-
operative UCLA activity scores were 6.0 and 6.7 for the hybrid and
uncemented groups, respectively (P ¼ .022). Average HHS at 2
years signiﬁcantly improved in both groups by approximately 45
points, but both preoperative (P ¼ .042) and postoperative HHS
(P ¼ .005) were reported higher on average for group 2. These
patients also reported lower average VAS pain scores than group
1 (1.1 vs 2.3 onworst days, P¼ .003, and 0.2 vs 0.5 on regular days,
P ¼ .049).
Although we lacked the quantitative data necessary for statis-
tically valid proof on extent of ﬁxation, a visual comparison of
microradiographs (Fig. 7) between cemented and uncemented
implants highlights the disparity between the 2 groups. Whereas
the microradiograph from group 1 shows fair penetration of the
cement into the bone, the microradiograph from group 2 shows
extensive bone growth into the porous implant surface, creating a
well-ﬁxed, living, stable bone-implant interface. Routine radio-
graphic analysis conﬁrmed that therewere no reported instances of
osteolysis or radiolucency observed in either group, with the
exception of cases ending in failure.
After our development of the Relative Acetabular Inclination
Limit (RAIL) guidelines in 2009 [43], which aims to prevent metal
ionwear through the optimal placement of acetabular components,
100% of group 2 implants (101/101 recorded values) were placed at
an appropriate steepness, whereas group 1 implants met RAIL
criteria in only 80% of cases (57/71 recorded values; P < .0001).
X-ray analysis revealed that the average AIA was signiﬁcantly less
steep in group 2, with an average angle of 46 for the hybrid group
and 36 for the uncemented group (P < .0001).
Concomitant metal ion data and reference values are presented
in Table 2. A signiﬁcantly higher percentage of patients in group 2
than in group 1 had normal ion levels (64% vs 34%; P ¼ .045).Table 5
Clinical and Radiographic Data.
Variable Group 1 Group 2 P Value
Clinical data
Harris hip score (Postoperative) 94 ± 11 98 ± 6 .005*
UCLA activity score 6.0 ± 2 6.7 ± 2 .022*
VAS paindregular day 0.5 ± 1 0.2 ± 1 .049*
VAS paindworst day 2.3 ± 3 1.1 ± 2 .003*
Radiographic data
Acetabular inclination angle () 45 ± 6 35 ± 4 <.0001*
Cases meeting RAIL (#/%) 57/71; 80 101/101; 100 <.0001*
Radiolucency (#/%) 0/75; 0 0/103; 0 1.000
Osteolysis (#/%) 0/75; 0 0/103; 0 1.000
Cases of radiolucency and osteolysis noted in the table exclude cases ending in
failure.
An asterisk (*) represents a statistical difference.
RAIL, Relative Acetabular Inclination Limit [43].
Fig. 7. On the left is a microradiograph of a spliced section of a cemented femoral component. The thick layer of cement has penetrated into the bone of the femoral head. On the
right is a microradiograph of a spliced section of a fully porous-coated, uncemented femoral component. The component is tightly wedged to the femoral head.
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cantly lower than bilateral group 1 cases (1.5 vs 3.5 mg/L; P¼ .0077).
There were no other signiﬁcant differences in the data. There were
no cases of AWRF in either group. After the 2007 implementation of
routine ion level collection at our clinic, substantially more metal
ion data were available (59% vs 24%, respectively; P < .0001), and
the interval from surgery to the procurement of ion levels was less
(3 vs 8 years; P < .001) for group 2 than group 1. Metal ion results
were converted from serum or plasma levels to whole blood levels
to facilitate analysis; this conversion occurred in 20% of cases from
group 1 and 18% of cases from group 2 (P ¼ .81). Rate of compliance
with metal ion testing was less for these ON groups compared to
the entire database (60% vs 74%; P < .0001).
Groups 1 and 2 were demographically similar (Table 1),
although patients from the uncemented group tended to score
higher preoperative HHS (P ¼ .042). Although these data indicate
more high-risk ON grades were present in group 2 (P ¼ .011),
there were signiﬁcantly more unrecorded Ficat grades in group 1Table 6
Literature Comparison Between Survivorship of Various Surgical Procedures for ON Patie
Study Procedure Prosthesis
Seyler et al [54] Nonvascularized bone grafting d
Yoo et al [55] Vascularized bone grafting d
Mont et al [56] Multiple drilling d
Song et al [57] Multiple drilling d
Mont et al [58] Core decompression d
Min et al [59] THA d
Garino et al [60] THA d
Kim et al [61] THA Cementless Spotorno
Bose et al [62] HRA Birmingham
Daniel et al [63] HRA Birmingham
Amstutz et al [64] HRA Conserve Plus
Revell et al [65] HRA Birmingham
Beaule et al [66] HRA Conserve/Conserve Plus
Aulakh et al [67] HRA d
Mont et al [68] HRA Conserve Plus
Present study, hybrid HRA Corin Cormet 2000/Biom
Present study, uncemented HRA Biomet fully porous-coat
FU, follow-up; THA, total hip arthroplasty; HRA, hip resurfacing arthroplasty; ON, osteon(P < .0001). The average follow-up duration for group 1 was 11
years (range, 8-14 years), and due to the uncemented femoral
component not becoming available until March 2007, group 2 had a
signiﬁcantly shorter average follow-up duration (P < .0001) with a
mean of 5.0 years (range, 2-8 years).
Discussion and Conclusions
These data support all 3 of our initial hypotheses: Our ﬁrst
hypothesis, that no more failures would occur from thermal ne-
crosis or other cement-related complications, holds true as evinced
by the complete elimination of femoral failures upon evolving to
uncemented, porous devices in 2008. Furthermore, the present
study veriﬁed our second hypothesis by validating an absence of
radiolucencies and component migration in all group 2 cases.
Finally, these data justiﬁed our third hypothesis because KM sur-
vivorship was signiﬁcantly greater at both the 2-year and 8-year
intervals. Simple visual inspection of the KM graphs (Figs. 2-5)nts.
Date Range Diagnosis Patient
Cohort
Average FU (y) Survivorship
Hips Female FU Rate
2002-2004 ON 39 41% 2 2 78.0%
1979-1995 ON 124 15% 12 12 89.0%
d ON 45 d 2 2 71.0%
d ON 163 d 7.2 7.2 88.0%
d ON 1206 d d d 63.5%
d ON 162 d 7.2 7.2 100%
d ON 123 40% 4.6 5 98.0%
1993-1995 ON 114 32% 9 10 97.8%
2000-2005 ON 96 16% 5.4 5.4 95.4%
1994-2003 ON 66 d 7.1 9.6 86.0%
1996-2006 ON 85 19% 7.6 8 93.9%
1994-2004 ON 73 29% 6.1 6.1 93.2%
1996-2002 ON 84 18% 4.9 4.9 96%
1997-2002 ON 101 23% 7.5 7 97.7%
2000-2003 ON 42 31% 3.2 3.2 94.5%
et hybrid 2001-2008 ON 75 25% 11.3 8
14
88.0%
84%
ed 2008-2013 ON 103 18% 5 8 100%
ecrosis.
R.J. O'Leary et al. / The Journal of Arthroplasty xxx (2016) 1e10 9should convince the reader of the dramatic difference between
these 2 ﬁxation study groups.
Despite unnecessary fears of AWRF arising from notorious
complications with DePuy ASR systems [44] and poor results at 1
major academic center [45], we found success in avoiding this
failure mode entirely in both groups of this study. We reported
similar success in 2014 in the largest AWRF study of its kind. Similar
to the ﬁndings of others [35], we found that steeper AIA correlated
to higher ion levels [43,46]. In the present study, mean AIA was
signiﬁcantly lower and more cases met the RAIL guideline in group
2, likely due to our focus heavily shifting onto optimal implant
alignment in 2007. Our previous study [43] discusses improve-
ments in surgical techniques to achieve this new goal, and the
present study's clinical outcomes reﬂect these advancements.
However, as there are no cases of AWRF in either cohort, this
intervention does not conﬂict with ﬁxationmethod and its effect on
overall change in failure rate.
We note these improvements in the failure rate as well as
clinical scores given that all were statistically superior for unce-
mented cases. Group 2 average HHS and VAS scores were improved
from group 1. Likewise, postoperative UCLA activity scores also
improved for group 2, which shows consistency with data from
others [47,48] and indicates, unlike stemmed THA [49], that high
activity does not increase the chance of implant failure with HRA.
This study contains several limitations, including 1 notable
shortcoming arising from the employment of nonconcurrent
groups. We previously determined [5] that all causes of failure are
reduced by greater surgeon experience with resurfacing using a
single implant. Smith [50] demonstrated that surgeons who
perform less than 5 HRA procedures per year achieve lower implant
survivorship with HRA than with THA at 5 years. In the present
study, group 1 cases were completed over the ﬁrst 7 years of the
senior author performing this operation, whereas group 2 were in
the subsequent 6 years of surgeries. Therefore, we recognize the
reasonable argument that these improved results potentially arose
from enhanced knowledge and technical skills rather than ad-
vancements in ﬁxation technique. However, the KM curve for
cemented implants only (Fig. 4) shows that there is no difference in
femoral survivorship based on improvement in surgical skill alone.
Additionally, the present 2-year comparison is valid. This compar-
ison, and the 100% implant survivorship at 8 years, certainly
convinces us to employ exclusively uncemented devices, elimi-
nating potential for a future randomized trial at our clinic. We
encourage others who still doubt the superiority of porous
ingrowth femoral ﬁxation in HRA to undertake such a comparison.
The second most notable limitation is the low rate of ion data ob-
tained for ON group 2, which is signiﬁcantly lower than in our
overall database. The cost and inconvenience of going to a special
laboratory seems to be too much for patients that show excellent
clinical outcome. Additionally, ON patients seem to be less
compliant with recommendations than our general patient popu-
lation, which we suspect may be due to the high rate of alcoholism.
The present study presents an 8-year implant survivorship of
100% in 103 consecutive uncemented hip resurfacings, exceeding
previously published results for osteotomy, bone grafting, stemmed
THA, and hybrid resurfacing in ON (Table 6). The present study of
178 patients represents the largest report of HRA for patients with
ON of the femoral head. Earlier studies of hybrid HRA in patients
with ON present survivorship percentages ranging from 86% to 98%
[16,24,26,28]. Our 100% success rate in the uncemented group, with
an average follow-up of 5 years (range, 2-8 years), is the best
reported midterm survival rate of HRA for ON, to our knowledge.
Although implant survivorship for HRA performed by expert
surgeons [51] are superior to those of THA in young men with OA
[52,53], resurfacings in certain high-risk subgroups, such as ON, havecontinued to exhibit undesirable durability similar to THA systems.
This study demonstrates that, with uncemented ﬁxation, HRA can be
dramatically improved for these challenging cases.Many resurfacing
surgeons have limited or abandoned hybrid resurfacing in ON
because of the less favorable results when compared to OA. Based on
the notable results reported herein, we suggest that these surgeons
consider uncemented resurfacing as an alternative.
1. HRA with porous ingrowth femoral components provides su-
perior clinical results and better implant survivorship than
cemented HRA in patients with ON.
2. 100% of uncemented resurfacings achieve stable ﬁxation in ON
by 2 years postoperation.
3. AWRF is rare in HRA for the treatment of ON of the femoral head,
which primarily occurs in young men (80% of ON cases).
4. Reducing AIA improves wear of metal bearings as shown by the
reduction of blood ion levels.
5. The results of uncemented HRA compare favorably with the
results of THA and other nonarthroplasty options for
advanced-stage ON.
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